secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2024-04-05T23:59:59+00:00
Accession:  0000950170-24-042291
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotech Q1 prelim rev ~$41-43M (+12% YoY); CFO Peterson departs, Piskel named
--------------------------------------------------------------------------------

- Preliminary total Q1 2024 revenue of ~$41-43M, up ~12% vs Q1 2023.
- MRD revenue ~$31-32M, up ~47% YoY; Immune Medicine revenue implied by difference.
- Strategic review concludes: run MRD and Immune Medicine internally with separate resources and segment reporting.
- CFO Tycho Peterson departs; Kyle Piskel (Principal Accounting Officer, 8-yr tenure) appointed full-time CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017024042291/0000950170-24-042291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017024042291/adpt-20240402.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-042291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer